In vitro safety “clinical trial” of the cardiac liability of drug polytherapy-Reference-Cited by-同舟云学术

In vitro safety “clinical trial” of the cardiac liability of drug polytherapy

Published:2021-05 Issue:3 Volume:14 Page:1155-1165
ISSN:1752-8054
Container-title:Clinical and Translational Science
language:en
Short-container-title:Clin Transl Sci

Author:

Charrez Bérénice¹,Charwat Verena¹,Siemons Brian¹,Finsberg Henrik²,Miller Evan W.³⁴⁵,Edwards Andrew G.⁶^ORCID,Healy Kevin E.¹⁷^ORCID

Affiliation:

1. Department of Bioengineering and California Institute for Quantitative Biosciences (QB3) University of California at Berkeley Berkeley California USA

2. Simula Research Laboratory Oslo Norway

3. Department of Chemistry University of California Berkeley California USA

4. Helen Wills Neuroscience Institute University of California, Berkeley Berkeley California USA

5. Department of Molecular and Cell Biology University of California at Berkeley Berkeley California USA

6. Department of Pharmacology School of Medicine University of California at Davis Davis California USA

7. Department of Materials Science and Engineering University of California at Berkeley Berkeley California USA

Funder

California Institute for Regenerative Medicine

National Heart, Lung, and Blood Institute

National Institute of General Medical Sciences

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,General Biochemistry, Genetics and Molecular Biology,General Medicine,General Neuroscience

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cts.13038

Reference49 articles.

1. Pérez‐BermejoJA KangS RockwoodSJ et al.SARS‐CoV‐2 infection of human iPSC‐derived cardiac cells predicts novel cytopathic features in hearts of COVID‐19 patients [published online ahead of print September 12 2020]. bioRxiv. https://doi.org/10.1101/2020.08.25.265561.

2. Cerebral Micro-Structural Changes in COVID-19 Patients – An MRI-based 3-month Follow-up Study

3. Association of Cardiac Infection With SARS-CoV-2 in Confirmed COVID-19 Autopsy Cases

4. COVID-19 and the kidney: what we think we know so far and what we don’t

5. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Short-term predictor for COVID-19 severity from a longitudinal multi-omics study for practical application in intensive care units;Talanta;2024-02

2. Heart-on-a-chip systems: disease modeling and drug screening applications;Lab on a Chip;2024

3. Taking the leap toward human-specific nonanimal methodologies: The need for harmonizing global policies for microphysiological systems;Stem Cell Reports;2024-01

4. Heart-on-a-chip platforms and biosensor integration for disease modeling and phenotypic drug screening;Biosensors and Bioelectronics;2023-01

5. Organ-on-a-chip meets artificial intelligence in drug evaluation;Theranostics;2023